India Bans Ashwagandha Leaf Use in Any Form, Industry Reacts

Why It Matters

The ban reshapes the global adaptogen market, forcing manufacturers to source root‑only material and potentially disrupting supply chains, farmer livelihoods, and regulatory standards worldwide.

Key Takeaways

• India restricts ashwagandha to root only, banning leaf extracts
• Ixoreal Biomed says its KSM‑66 root supply already complies
• Sabinsa and Kerry dispute the ban, citing safety data for leaf
• EU regulators also reviewing ashwagandha safety, possible continent‑wide ban
• Ban could affect up to 300,000 Indian agricultural workers

Pulse Analysis

India’s recent FSSAI directive marks a decisive regulatory shift for ashwagandha, one of the world’s most traded adaptogens. By mandating root‑only use, the agency cites a 2024 safety dossier that highlights elevated levels of reactive withanolides—particularly withaferin A—in leaf material, raising concerns over hepatotoxicity and hormonal effects. This aligns with traditional Ayurvedic practice, which has long favored the root, but it also reflects mounting scientific scrutiny as Europe grapples with liver‑injury signals and prepares a possible EU‑wide ban under the Article 8 procedure. The policy underscores how emerging safety data can rapidly translate into market‑wide restrictions.

Industry players have responded along a spectrum of compliance and contestation. Ixoreal Biomed, the maker of KSM‑66, proudly notes its pre‑existing root‑only supply chain, positioning itself as a low‑risk partner for global formulators. Conversely, Sabinsa and Kerry, both major leaf‑extract manufacturers, argue that extensive toxicology studies demonstrate comparable safety to root extracts and are actively appealing the decision. Their pushback highlights a broader scientific debate: while in‑vitro studies suggest withaferin A’s cytotoxic potential, in‑vivo human data remain inconclusive. The divergent stances illustrate the tension between precautionary regulation and evidence‑based product development.

Beyond regulatory headlines, the ban carries profound economic and supply‑chain ramifications. India cultivates roughly 25,000 acres of ashwagandha annually, supporting up to 300,000 rural workers whose livelihoods depend on both root and leaf harvests. Limiting harvests to roots could compress farmer incomes and reshape export dynamics, forcing global brands to audit sourcing, adopt stricter authentication methods, and potentially recalibrate pricing. As the industry adapts, the episode underscores the need for harmonized pharmacopeial standards and transparent withanolide testing to safeguard both consumer safety and the sustainability of the ashwagandha value chain.